Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy

Ruff Paul; Ferry David R.; Lakomy Radek; Prausova Jana; Van Hazel Guy A.; Hoff Paulo M.; Cunningham David; Arnold Dirk; Schmoll Hans J.; Moiseyenko Vladimir M.; McKendrick Joseph J.; ten Tije Albert J.; Vishwanath Raghu L.; Bhargava Pankaj; Chevalier Soazig; Macarulla Teresa; Van Cutsem Eric

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy

【24h】

Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy

机译：在以前的欧洲依氯蛋白的治疗患者中与转移结直肠癌患者的患者的安全性和疗效的时间课程

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Patients with metastatic colorectal cancer (mCRC) previously-treated with oxaliplatin benefit significantly from the addition of aflibercept to FOLFIRI in relation to overall survival, progression-free survival and response rate.

机译：背景：从奥沙利铂中的转移性结直肠癌（MCRC）显着地从加入到整体存活，无进展的存活率和反应率方面的ofliBliplatiN益处，显着损益。

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2015年第24期|共9页
作者
Ruff Paul; Ferry David R.; Lakomy Radek; Prausova Jana; Van Hazel Guy A.; Hoff Paulo M.; Cunningham David; Arnold Dirk; Schmoll Hans J.; Moiseyenko Vladimir M.; McKendrick Joseph J.; ten Tije Albert J.; Vishwanath Raghu L.; Bhargava Pankaj; Chevalier Soazig; Macarulla Teresa; Van Cutsem Eric;
展开▼
作者单位

Univ Witwatersrand Fac Hlth Sci ZA-2193 Johannesburg South Africa;

Russells Hall Hosp Dudley W Midlands England;

Masaryk Mem Canc Inst Brno Czech Republic;

Fak Nemocnice Motole Prague Czech Republic;

Univ Western Australia Nedlands WA 6009 Australia;

Hosp Sirio Libanes Ctr Oncol Sao Paulo Brazil;

Royal Marsden Hosp Sutton Surrey England;

Tumor Biol Ctr Dept Med Oncol Freiburg Germany;

Univ Halle Wittenberg Halle Germany;

Oncol Res Inst Na NN Petrov St Petersburg Russia;

Monash Univ Clayton Vic 3800 Australia;

Amphia Hosp Breda Netherlands;

Sanofi Global Oncol Med Affairs Cambridge MA USA;

Sanofi Global Oncol Res &

Dev Cambridge MA USA;

Sanofi Vitry Sur Seine France;

Univ Autonoma Barcelona Vall dHebron Univ Hosp E-08193 Barcelona Spain;

Univ Hosp Leuven Leuven Belgium;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Aflibercept; Colorectal cancer; Efficacy; Safety; VEGF-A; VEGF-B; PlGF;

机译：aflibercept;结肠直肠癌;疗效;安全;VEGF-A;VEGF-B;PLGF;

相似文献

外文文献
中文文献
专利

1. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy [J] . Ruff Paul, Ferry David R., Lakomy Radek, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2015,第1a24期

机译：在先前以奥沙利铂为基础的治疗进展的转移性结直肠癌患者中，阿柏西普联合FOLFIRI的安全性和有效性的时程
2. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence [J] . Wade Ros, Duarte Ana, Simmonds Mark, PharmacoEconomics . 2015,第5期

机译：Aflibercept联合伊立替康和氟尿嘧啶为基础的疗法（FOLFIRI）治疗转移性结直肠癌的临床和成本效益：先前基于奥沙利铂的化学疗法已取得进展：证据的批评
3. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy [J] . Van Cutsem Eric, Joulain Florence, Hoff Paulo M., Targeted oncology . 2016,第3期

机译：Aflibercept Plus FOLFIRI与安慰剂Plus FOLFIRI在二线转移性结直肠癌中的关系：III期VELOR研究的生存率事后分析，分析排除了在完成基于奥沙利铂辅助治疗的患者中或治疗后6个月内复发的患者
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. New Models of Colorectal Cancer to Facilitate Therapy Development for Metastatic Disease [D] . O'Rourke, Kevin. 2017

机译：新型结肠直肠癌促进转移性疾病治疗的疗效
6. Safety and Efficacy of Combined Yttrium 90 Resin Radioembolization with Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal Cancer [O] . Andre De Souza, Kevin Pelham Daly, James Yoo, 2015

机译：钇90树脂放射栓塞联合阿柏西普和FOLFIRI在转移性结直肠癌患者中的安全性和有效性
7. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy [O] . Ruff Paul, Ferry David R., Lakomỳ Radek, 2015

机译：在先前以奥沙利铂为基础的治疗进展的转移性结直肠癌患者中，阿柏西普联合FOLFIRI的安全性和疗效的时程

Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy

摘要

著录项

相似文献

相关主题

期刊订阅